Your browser doesn't support javascript.
loading
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
Vanderstichele, Adriaan; Loverix, Liselore; Busschaert, Pieter; Van Nieuwenhuysen, Els; Han, Sileny N; Concin, Nicole; Callewaert, Tiene; Olbrecht, Siel; Salihi, Rawand; Berteloot, Patrick; Neven, Patrick; Lambrechts, Diether; Van Gorp, Toon; Vergote, Ignace.
Affiliation
  • Vanderstichele A; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Loverix L; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Busschaert P; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Laboratory for Translational Genetics, Department of Oncolo
  • Van Nieuwenhuysen E; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Han SN; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Concin N; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Callewaert T; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Olbrecht S; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Salihi R; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Berteloot P; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Neven P; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Lambrechts D; Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Leuven, Belgium; Center for Cancer Biology, VIB, Leuven, Belgium.
  • Van Gorp T; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Vergote I; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium; Laboratory of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium. Electronic address: ignace.vergote@uzleuven.be.
Gynecol Oncol ; 165(1): 14-22, 2022 04.
Article in En | MEDLINE | ID: mdl-35177277
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Physicians Type of study: Clinical_trials / Etiology_studies Limits: Female / Humans Language: En Journal: Gynecol Oncol Year: 2022 Type: Article Affiliation country: Belgium
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Physicians Type of study: Clinical_trials / Etiology_studies Limits: Female / Humans Language: En Journal: Gynecol Oncol Year: 2022 Type: Article Affiliation country: Belgium